Kwangdong Phar (009290) - Total Liabilities

Latest as of December 2025: ₩608.53 Billion KRW ≈ $412.39 Million USD

Based on the latest financial reports, Kwangdong Phar (009290) has total liabilities worth ₩608.53 Billion KRW (≈ $412.39 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Kwangdong Phar - Total Liabilities Trend (2011–2025)

This chart illustrates how Kwangdong Phar's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Kwangdong Phar's working capital to evaluate short-term liquidity relative to the company's equity base.

Kwangdong Phar Competitors by Total Liabilities

The table below lists competitors of Kwangdong Phar ranked by their total liabilities.

Company Country Total Liabilities
Heran Co Ltd
TW:5283
Taiwan NT$3.23 Billion
Financiera Independencia S.A.B. de C.V. SOFOM E.N.R
MX:FINDEP
Mexico MX$6.28 Billion
Temapol Polimer Plastik ve Insaat Sanayi Ticaret AS
IS:TMPOL
Turkey TL1.15 Billion
Lindsay Australia Ltd
AU:LAU
Australia AU$553.18 Million
Eastern Communications Co Ltd B
SHG:900941
China $847.86 Million
Prosafe SE
OL:PRS
Norway Nkr351.70 Million
Kafrit
TA:KAFR
Israel ILA616.98 Million
Takkt AG
XETRA:TTK
Germany €359.50 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Kwangdong Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kwangdong Phar (009290) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.36 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.93 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kwangdong Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kwangdong Phar (2011–2025)

The table below shows the annual total liabilities of Kwangdong Phar from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩608.53 Billion
≈ $412.39 Million
+10.24%
2024-12-31 ₩552.01 Billion
≈ $374.09 Million
+12.65%
2023-12-31 ₩490.02 Billion
≈ $332.08 Million
+27.28%
2022-12-31 ₩384.98 Billion
≈ $260.89 Million
+7.96%
2021-12-31 ₩356.60 Billion
≈ $241.66 Million
+8.57%
2020-12-31 ₩328.46 Billion
≈ $222.59 Million
-4.88%
2019-12-31 ₩345.32 Billion
≈ $234.02 Million
+14.64%
2018-12-31 ₩301.22 Billion
≈ $204.13 Million
-1.69%
2017-12-31 ₩306.40 Billion
≈ $207.64 Million
+9.39%
2016-12-31 ₩280.10 Billion
≈ $189.82 Million
-2.08%
2015-12-31 ₩286.06 Billion
≈ $193.86 Million
+123.25%
2014-12-31 ₩128.13 Billion
≈ $86.83 Million
-4.98%
2013-12-31 ₩134.85 Billion
≈ $91.39 Million
+10.39%
2012-12-31 ₩122.16 Billion
≈ $82.79 Million
+69.28%
2011-12-31 ₩72.16 Billion
≈ $48.91 Million
--

About Kwangdong Phar

KO:009290 Korea Packaged Foods
Market Cap
$150.30 Million
₩221.79 Billion KRW
Market Cap Rank
#17740 Global
#755 in Korea
Share Price
₩6050.00
Change (1 day)
-2.58%
52-Week Range
₩5600.00 - ₩11080.00
All Time High
₩11611.32
About

Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more